-
Innovation Ranking
NewInnovation Ranking – Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd (Teva) discovers, develops, manufactures, and commercializes generic and specialty medicines. The company provides specialty medicines to treat disorders of the central nervous system (CNS), cancer, respiratory, dermatology, women’s health, and other disease conditions. It offers generic medicines in a range of dosage forms including capsules, tablets, injectables, liquids, inhalants, creams, and ointments. Teva also provides over-the-counter (OTC) products, besides active pharmaceutical ingredients (APIs). It focuses on developing new generic drugs. The company conducts its worldwide operations...
-
Product Insights
NewNet Present Value Model: Teva Pharmaceutical Industries Ltd’s Golimumab Biosimilar
Empower your strategies with our Net Present Value Model: Teva Pharmaceutical Industries Ltd's Golimumab Biosimilar report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Teva Pharmaceutical Industries Ltd’s Aflibercept Biosimilar
Empower your strategies with our Net Present Value Model: Teva Pharmaceutical Industries Ltd's Aflibercept Biosimilar report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Teva Pharmaceutical Industries Ltd’s Denosumab Biosimilar
Empower your strategies with our Net Present Value Model: Teva Pharmaceutical Industries Ltd's Denosumab Biosimilar report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Teva Pharmaceutical Industries Ltd’s Olanzapine ER
Empower your strategies with our Net Present Value Model: Teva Pharmaceutical Industries Ltd's Olanzapine ER report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Teva Pharmaceutical Industries Ltd’s Omalizumab Biosimilar
Empower your strategies with our Net Present Value Model: Teva Pharmaceutical Industries Ltd's Omalizumab Biosimilar report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Teva Pharmaceutical Industries Ltd’s Uzedy
Empower your strategies with our Net Present Value Model: Teva Pharmaceutical Industries Ltd's Uzedy report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Teva Pharmaceutical Industries Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Teva Pharmaceutical Industries Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
NewReproductive Health Devices Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Reproductive Health Devices Pipeline Market Report Overview Endometrial ablation devices, female sterilization devices, reversible contraceptive devices, and assisted reproductive technology devices are the main categories of reproductive health devices. The reproductive health devices pipeline report provides comprehensive information about the main products with their comparative segment-wise analysis at various stages of development. The report also covers the regional and country-wise reproductive health devices clinical trials outlook. The regulatory paths followed for conducting the reproductive health devices pipeline research are also...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vididencel in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vididencel in Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vididencel in Ovarian Cancer Drug Details: vididencel is under development for the...